A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer

Trial Profile

A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs VS 4718 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Verastem
  • Most Recent Events

    • 24 Jan 2017 Status changed from recruiting to discontinued due to company's decision to de-prioritize 4718 development
    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top